Bluebird Bio Inc. (NASDAQ:BLUE) rose 5.2% during trading on Wednesday . The company traded as high as $47.43 and last traded at $47.33, with a volume of 311,485 shares changing hands. The stock had previously closed at $44.98.

BLUE has been the subject of a number of recent analyst reports. BTIG Research reiterated a “buy” rating and issued a $72.00 price objective on shares of Bluebird Bio in a report on Sunday, April 3rd. Zacks Investment Research upgraded Bluebird Bio from a “sell” rating to a “hold” rating in a report on Tuesday, April 5th. Leerink Swann reiterated an “outperform” rating and issued a $67.00 price objective on shares of Bluebird Bio in a report on Tuesday, April 5th. Vetr downgraded Bluebird Bio from a “strong-buy” rating to a “buy” rating and set a $55.90 price objective for the company. in a report on Wednesday, April 6th. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating and issued a $149.00 price objective on shares of Bluebird Bio in a report on Monday, April 11th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $96.09.

The company’s market capitalization is $1.81 billion. The company’s 50-day moving average is $44.29 and its 200 day moving average is $45.69.

Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, May 4th. The company reported ($1.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by $0.29. The business earned $1.50 million during the quarter, compared to analysts’ expectations of $4.50 million. The company’s revenue for the quarter was down 76.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.76) earnings per share. Equities analysts predict that Bluebird Bio Inc. will post ($5.90) EPS for the current fiscal year.

In other news, insider David Davidson sold 1,000 shares of Bluebird Bio stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $38.73, for a total value of $38,730.00. Following the completion of the transaction, the insider now directly owns 10,600 shares of the company’s stock, valued at approximately $410,538. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Philip D. Gregory sold 2,931 shares of Bluebird Bio stock in a transaction dated Thursday, June 16th. The stock was sold at an average price of $39.52, for a total value of $115,833.12. Following the completion of the transaction, the insider now directly owns 30,069 shares of the company’s stock, valued at $1,188,326.88. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have bought and sold shares of the company. Jennison Associates LLC raised its position in Bluebird Bio by 171.3% in the fourth quarter. Jennison Associates LLC now owns 864,314 shares of the company’s stock valued at $55,506,000 after buying an additional 545,727 shares during the period. Wells Fargo & Company MN raised its position in Bluebird Bio by 53.4% in the fourth quarter. Wells Fargo & Company MN now owns 474,832 shares of the company’s stock valued at $30,492,000 after buying an additional 165,303 shares during the period. State of Tennessee Treasury Department raised its position in Bluebird Bio by 45.4% in the fourth quarter. State of Tennessee Treasury Department now owns 191,963 shares of the company’s stock valued at $12,328,000 after buying an additional 59,952 shares during the period. New York State Common Retirement Fund raised its position in Bluebird Bio by 27.8% in the fourth quarter. New York State Common Retirement Fund now owns 171,022 shares of the company’s stock valued at $10,983,000 after buying an additional 37,178 shares during the period. Finally, Marshall Wace LLP raised its position in Bluebird Bio by 374.8% in the fourth quarter. Marshall Wace LLP now owns 168,427 shares of the company’s stock valued at $10,816,000 after buying an additional 132,956 shares during the period.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.